Oct 30 (Reuters) - Newlink Genetics Corp
* Newlink Genetics announces FDA orphan-drug designation for Indoximod
* Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.